A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Clinical trial NCT03000452 · COMPLETED
Trial details
- NCT number
- NCT03000452
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-14
- Primary completion
- 2017-09-18
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.